Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
DOW Dow Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Price
Delayed
$0.6297
Day's Change
-0.0319 (-4.82%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6599
Day's Low
0.6001
Volume
(Heavy Day)

Today's volume of 1,924,719 shares is on pace to be much greater than NBRV's 10-day average volume of 2,903,555 shares.

1,924,719

IQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 15, 2020 in the Class Action Filed on Behalf of iQIYI, Inc. Limited Shareholders

12:24 pm ET June 1, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - June 1, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of iQIYI, Inc. (NASDAQ: IQ) alleging that the Company violated federal securities laws.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/56994_772912_logo.jpg

The IQ lawsuit is on behalf of persons and entities other than Defendants that purchased or otherwise acquired: (a) iQIYI American Depository Shares pursuant and/or traceable to the Company's initial public offering conducted on or about March 29, 2018; or (b) iQIYI securities between March 29, 2018, and April 7, 2020.

Lead Plaintiff Deadline: June 15, 2020

Learn more about your recoverable losses in DNK:

http://www.kleinstocklaw.com/pslra-1/iqiyi-inc-loss-submission-form?id=7040&from=5

The filed complaint alleges that iQIYI, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) iQIYI inflated its revenue figures; (2) iQIYI inflated its user numbers; (3) iQIYI inflated its expenses to cover up other fraud; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Shareholders have until June 15, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the IQ lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56994

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.